Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Fosrenol (Lanthanum Carbonate)
Takeda
Chronic Kidney Disease, Stage 5
1 trial -
GA-GCB (velaglucerase alfa)
Takeda
Gaucher Disease
1 trial -
GLASSIA
Takeda
Graft Versus Host Disease
1 trial -
GLASSIA
Takeda
Alpha1-antitrypsin Deficiency
1 trial -
HYQVIA
Takeda
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
2 trials -
High Dose Colchicine (4.8 mg total dose)
Takeda
Gout
1 trial -
Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)
Takeda
Hemophilia A
1 trial -
HyQvia 100 mg/ml solution for infusion for subcutaneous use, HyQvia 100 mg/ml solution for infusion for subcutaneous use, TAK-881
Takeda
Primary Immunodeficiency Diseases
1 trial -
IBI363
Takeda
iO Resistant sqNSCLC
1 trial -
IGI, 10%
Takeda
Multiple Myeloma
1 trial -
IGSC 20% infusion
Takeda
Primary Immunodeficiency Disease
1 trial -
IXAZOMIB
Takeda
Relapsed or Refractory Systemic Light Chain Amyloidosis
1 trial -
Icatibant
Takeda
Angioedema
1 trial -
Icatibant
Takeda
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
1 trial -
Icatibant
Takeda
Hereditary Angioedema
3 trials -
Iduronate-2-sulfatase enzyme replacement therapy
Takeda
Mucopolysaccharidosis II
1 trial -
Idursulfase (idursulfase-IT [HGT-2310])
Takeda
Hunter Syndrome and Cognitive Impairment
1 trial -
Immune Globulin Infusion (Human), 10%
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Immune Globulin Intravenous (Human), 10%
Takeda
Primary Immunodeficiency Diseases (PID)
2 trials -
Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Takeda
AlzheimerΒ΄s Disease
1 trial -
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg
Takeda
AlzheimerΒ΄s Disease
1 trial -
Immune Globulin Intravenous (Human), 10% Solution
Takeda
AlzheimerΒ΄s Disease
1 trial -
Immune Globulin Intravenous (Human), 10% Solution
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
Immune Globulin Intravenous (IGIV)
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources